Español
Interview with Ana Isabel Jiménez, Managing Director of Sylentis, on the occasion of OTS Budapest 2025
From 19 to 22 October 2025, Sylentis will participate in the Oligonucleotide Therapeutics Society (OTS) conference in Budapest, a key international meeting point for the advancement of oligonucleotide-based therapies.
In this context, Ana Isabel Jiménez, Managing Director of Sylentis, will present poster P-113 on SYL1801, a new siRNA-based treatment for neovascular macular degeneration (AMD).
We took the opportunity to talk to her about this milestone, Sylentis’ innovation strategy and the role played by SYOLIGO.
You will be presenting poster P-113 on SYL1801, a new siRNA-based treatment for neovascular macular degeneration (AMD). What does this milestone mean for Sylentis and for research into eye therapies?
The presentation of the results obtained in the SYL1801 clinical trial is a very important step for Sylentis in order to share and discuss with experts in the technology at the OTS conference.
This new candidate demonstrates the potential of siRNA as a therapeutic tool for addressing complex eye diseases such as neovascular macular degeneration, a condition that has a significant impact on quality of life and for which there are still unmet medical needs.
For Sylentis, it strengthens our position as one of the leading European companies in the field of therapeutic oligonucleotides for the treatment of eye diseases.
How does SYL1801 fit into Sylentis’ innovation strategy?
SYL1801 fits squarely within Sylentis’ strategy of combining biotechnological innovation with a translational approach. Our goal is to bring RNA interference science to patients in the most effective and safe manner possible.
It forms part of a strategic line focused on ophthalmological pathologies with high prevalence and unmet therapeutic needs, while allowing us to leverage the knowledge accumulated in the development of other RNA interference programmes.
Furthermore, it reflects our commitment to developing our own projects while also establishing partnerships that accelerate the arrival of these therapies on the market.
From your perspective as Managing Director, what opportunities does having a pioneering CDMO in therapeutic oligonucleotides open up for Spain and Europe?
Having a CDMO specialising in oligonucleotides in Spain and Europe is a strategic opportunity. It reduces dependence on third countries, strengthens technological autonomy and positions Europe as a key player in the manufacture of innovative therapies.
For Sylentis, this represents another step forward in the value chain: not only do we develop innovative molecules, but we also offer industrial and development capacity to other companies in the biotechnology and pharmaceutical sector.
At the national and European level, this involves creating skilled jobs, attracting investment and promoting knowledge transfer in an innovative field such as RNA-based therapies.
Sylentis takes a decisive step towards consolidating a robust and competitive RNA biotechnology sector in Europe. The combination of scientific innovation, industrial capacity and strategic collaboration makes the company a key player in the therapeutic oligonucleotide ecosystem and advanced pharmaceutical manufacturing.
